Pentamidine disrupt trafficking of two structurally different potassium channels, which can precipitate life-threatening arrhythmia. We demonstrate that a single drug can interfere in cardiac potassium channel trafficking in a subtype specific mode and that this adverse drug effect can be corrected in a channel specific manner.